Many immunohistochemical studies define a mutant protein as occurring when neoplasms show a nuclear immunoreaction for p53 in more than 10% of the tumour cells [4, 18, 21], while other studies chose a rate of more than 20% [29, 31] or 40% [28, 32, 33] of the tumour cells as their cutoff value. Here, TP53 is linked to neoplasm.